Latest Manufacturing News

Page 2 of 335
Epiminder has signed a five-year rolling partnership with Stratus Neuro to integrate its long-term Minder EEG data into StratusEEG, a cloud platform used by more than 7,000 US clinicians and administrators. The agreement gives Epiminder an established clinical workflow for its DETECT study and planned US commercialisation, although no financial terms or launch date were disclosed.
Victor Sage
Victor Sage
17 Nov 2026
Clover Corporation has entered FY27 with stronger margins, no interest-bearing debt and revenue momentum after reporting a 50% rise in FY26 NPAT. The company expects first-half FY27 revenue of about $60 million and says full-year revenue and earnings could outperform FY26 if current conditions persist.
Victor Sage
Victor Sage
17 Nov 2026
AdAlta has taken ownership of the US FDA Orphan Drug Designation for EW-001, strengthening the commercial case for its mesothelioma CAR-T therapy. The designation follows a constructive pre-IND meeting, but approval and clinical success remain unproven.
Ada Torres
Ada Torres
17 Nov 2026
First Graphene has signed a three-year agreement with China-based UNITEX to develop and commercialise graphene-enhanced carbon fibre prepreg and other advanced materials. The partnership offers manufacturing and customer access, but revenue, volumes and a commercial launch remain uncommitted.
Victor Sage
Victor Sage
16 Nov 2026
Neurizon has opened a non-underwritten A$2 million share purchase plan at A$0.068 a share, giving eligible shareholders access to the same terms as its recent placement. Participants may also receive one free option for each new share, subject to shareholder approval and ASX quotation conditions, as the company funds its NUZ-001 ALS program towards a late Q2 2027 readout.
Ada Torres
Ada Torres
16 Nov 2026
Vectus Biosystems has received supportive written FDA feedback on VB0004, reducing uncertainty around the drug candidate’s manufacturing, nonclinical and planned clinical development package. The company will now incorporate the guidance into an IND application for a Phase Ib/IIa study in IPF patients in Australia.
Ada Torres
Ada Torres
16 Nov 2026
ClearVue Technologies has secured a letter of award for solar cladding on a government-owned building in Singapore, with the subcontract valued at up to A$859,000. The project gives the company a sizeable regional reference site, although the award remains subject to final design, scope and manufacturing approvals.
Victor Sage
Victor Sage
16 Nov 2026
Amari Metals Australia has launched a NZ$1.65-per-share cash offer for Metro Performance Glass, valuing control at a 64.2% premium to the last NZX close. Its existing 51% shareholder lock-up makes the acceptance threshold largely academic, but the path to a full delisting still depends on minority holders and outstanding offer conditions.
Victor Sage
Victor Sage
16 Nov 2026
Wide Open Agriculture has secured a $1 million placement to fund manufacturing trials, commercial development and working capital as it targets a return to lupin ingredient production in Q2 2027. The raise strengthens its cash position, but production still depends on selecting a partner and completing technical validation.
Victor Sage
Victor Sage
13 Nov 2026
Imricor Medical Systems (ASX:IMR) has moved from regulatory preparation into US commercial deployment, signing its first two NorthStar hospital customers within weeks of launch. The milestone comes with sharply higher quarterly revenue, a fresh Philips pathway and a still-heavy cash burn.
Victor Sage
Victor Sage
13 Nov 2026
Applied Materials closed fiscal 2026 with record quarterly and annual revenue, expanding margins and a stronger-than-expected-looking first-quarter revenue target, although the filing gives no analyst consensus comparison. The semiconductor equipment maker also disclosed a US$253 million export-controls settlement and increased its strategic investment in Besi.
Victor Sage
Victor Sage
13 Nov 2026
SIV Capital has agreed to acquire underground mining equipment group PPKME in a proposed scheme valued at about $18.6 million. The transaction could finally give SIV an operating business and a route back to ASX trading, but it still faces funding, shareholder, court and listing hurdles.
Victor Sage
Victor Sage
12 Nov 2026

Browse the archive

Full archive